spacer
home > ebr > autumn 2018 > applying affimers
PUBLICATIONS
European Biopharmaceutical Review

Applying Affimers

Pharmacokinetic (PK) assays are a key component of drug development and clinical follow-up processes, with the global PK assay service market currently valued at US $652.8 million (1). Results from PK assays are critical in all phases of drug development, and numerous decisionmaking milestones in drug development programmes rely, at least in part, on PK assay results and the exposure-response relationships based on pharmacodynamic (PD) endpoints or clinical endpoints. Companies are increasingly using data from drug monitoring assays at all stages of the development pipeline to enhance the productivity and efficiency of new drug development processes (2).

Both PK and PD assays require critical reagents (eg, anti-drug reagents/anti-idiotypic binders) that can specifically and accurately measure the drug in plasma and tissues. Sensitive and reproducible PK assays are required as part of the complex and lengthy development process for new therapeutic molecules. These drug monitoring assays must be well-characterised, fully validated, and documented to yield reliable results compliant with the necessary regulatory standards.

Antibodies currently represent the ‘gold standard’ of affinity reagents, and, while traditional antibodies have been refined to the point where they are specific, sensitive, and reasonably reliable, these can be limited by development speed, complexity to produce on an industrial scale, and lotto- lot variation in assay performance.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Amanda Nicholl is Senior Assay Development Scientist at Avacta, where she applies her experience in molecular and cellular biology in both academic and industrial environments to develop assays and generate data to exemplify the use of affimer technology.
spacer
Dr Amanda Nicholl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement